LTR Pharma

LTR Pharma has entered into an exclusive pilot commercialisation agreement with Marius Pharmaceuticals, a US pharmaceutical company focused on men’s health, to introduce Marius’ lead product, KYZATREX® (testosterone undecanoate oral capsules), in Australia. KYZATREX is FDA-approved and commercially available in the United States.   Strategic rationale  Testosterone deficiency affects energy, mood,

LTR Pharma has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc., a leading U.S. Section 503A compounding pharmacy, converting the previously announced binding Term Sheet into a definitive commercial agreement governing the planned manufacturing, compounding, fulfilment and nationwide supply of ROXUS® in the United States.  The agreement establishes the operational framework for

LTR Pharma has executed a definitive Telehealth Distribution Agreement with Shed Holdings LLC, a leading U.S. direct-to-consumer telehealth platform, converting the previously announced binding Term Sheet into a definitive commercial agreement governing the planned U.S. commercialisation of ROXUS®. The agreement establishes the commercial framework for the planned U.S. commercialisation of ROXUS. Shed will commercialise